www.fdanews.com/articles/186903-novel-preventive-treatment-for-adult-migraines-approved-by-fda
![Grey Approved Stamp](https://www.fdanews.com/ext/resources/test/Drug-Images4/Grey_Approved_Stamp.gif?t=1576541258&width=430)
Novel Preventive Treatment for Adult Migraines Approved by FDA
May 21, 2018
The FDA approved Novartis and Amgen’s Aimovig (erenumab-aooe), making it the first agency-approved preventive migraine treatment in a new drug class that blocks the activity of calcitonin gene-related peptide, a molecule involved in migraines.
The medicine’s effectiveness was evaluated in three clinical trials. In one 667-patient trial, those treated with the medication experienced two and a half fewer monthly migraine days on average.
The trials determined that the medication significantly reduced migraine frequency, the effects on daily activities and the use of acute migraine-specific medication over a period of six months.